{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:30:50Z","timestamp":1793374250084,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier","isbn-type":[{"value":"9780128201893","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.apha.2020.05.002","type":"book-chapter","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T07:37:40Z","timestamp":1592638660000},"page":"237-259","source":"Crossref","is-referenced-by-count":14,"title":["Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants"],"prefix":"10.1016","member":"78","reference":[{"issue":"2","key":"10.1016\/bs.apha.2020.05.002_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.apha.2020.05.002_bb0015","author":"Agency for Healthcare Research and Quality"},{"issue":"4","key":"10.1016\/bs.apha.2020.05.002_bb0020","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/JCP.0000000000000717","article-title":"Oral ketamine in treatment-resistant depression: A clinical effectiveness case series","volume":"37","author":"Al Shirawi","year":"2017","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2020.05.002_bb0025","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott","year":"2018","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1590\/1516-4446-2017-2380","article-title":"Maintenance use of ketamine for treatment-resistant depression: An open-label pilot study","volume":"40","author":"Barenboim","year":"2018","journal-title":"Revista Brasileira de Psiquiatria"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","article-title":"Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability","volume":"12","author":"Benedict","year":"1998","journal-title":"The Clinical Neuropsychologist"},{"key":"10.1016\/bs.apha.2020.05.002_bb0040","first-page":"2165","article-title":"Validity of a screening tool for detecting subtle cognitive impairment in the middle-aged and elderly","volume":"9","author":"Bruce","year":"2014","journal-title":"Clinical Interventions in Aging"},{"issue":"10128","key":"10.1016\/bs.apha.2020.05.002_bb0045","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/bs.apha.2020.05.002_bb0050","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41386-019-0365-0","article-title":"Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: A randomized controlled trial","volume":"44","author":"Costi","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0004867416631828","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation","volume":"51","author":"Cusin","year":"2017","journal-title":"The Australian and New Zealand Journal of Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2020.05.002_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: Results of a double-blind, doubly-randomized, placebo-controlled study","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/bs.apha.2020.05.002_bb0065","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/bs.apha.2020.05.002_bb0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/bs.apha.2020.05.002_bb0075","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/bs.apha.2020.05.002_bb0080","author":"Food and Drug Administration"},{"key":"10.1016\/bs.apha.2020.05.002_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jad.2015.02.011","article-title":"Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders","volume":"178","author":"Forte","year":"2015","journal-title":"Journal of Affective Disorders"},{"issue":"10159","key":"10.1016\/bs.apha.2020.05.002_bb0090","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/bs.apha.2020.05.002_bb0095","first-page":"1","article-title":"Practice guidelines for the treatment of patients with major depressive disorder","volume":"167","author":"Gelenberg","year":"2010","journal-title":"The American Journal of Psychiatry"},{"issue":"11","key":"10.1016\/bs.apha.2020.05.002_bb0100","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jagp.2017.06.007","article-title":"Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression","volume":"25","author":"George","year":"2017","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"6","key":"10.1016\/bs.apha.2020.05.002_bb0105","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.apha.2020.05.002_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2016.05.076","article-title":"Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial","volume":"204","author":"Jafarinia","year":"2016","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1520-6394(1998)7:1<3::AID-DA2>3.0.CO;2-F","article-title":"Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey","volume":"7","author":"Kessler","year":"1998","journal-title":"Depression and Anxiety"},{"issue":"1\u20132","key":"10.1016\/bs.apha.2020.05.002_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0327(97)00056-6","article-title":"Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey","volume":"45","author":"Kessler","year":"1997","journal-title":"Journal of Affective Disorders"},{"issue":"10","key":"10.1016\/bs.apha.2020.05.002_bb0125","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/da.20740","article-title":"Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: A randomized, placebo-controlled trial depression and anxiety","volume":"27","author":"Liebowitz","year":"2010","journal-title":"Depression and Anxiety"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"The International Journal of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: A review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","article-title":"Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study","volume":"105","author":"Morgan","year":"2010","journal-title":"Addiction"},{"issue":"10","key":"10.1016\/bs.apha.2020.05.002_bb0145","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"The American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2020.05.002_bb0150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biological Psychiatry"},{"issue":"10","key":"10.1016\/bs.apha.2020.05.002_bb0155","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"The American Journal of Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2020.05.002_bb0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.1016\/bs.apha.2020.05.002_bb0165","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"The American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/bs.apha.2020.05.002_bb0170","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"The American Journal of Psychiatry"},{"issue":"8","key":"10.1016\/bs.apha.2020.05.002_bb0175","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1176\/ajp.153.8.985","article-title":"Resistance to antidepressant medications and short-term clinical response to ECT","volume":"153","author":"Prudic","year":"1996","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/bs.apha.2020.05.002_bb0180","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"The American Journal of Psychiatry"},{"issue":"10","key":"10.1016\/bs.apha.2020.05.002_bb0185","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.285.10.1299","article-title":"Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: A randomized controlled trial","volume":"285","author":"Sackeim","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"4","key":"10.1016\/bs.apha.2020.05.002_bb0190","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/bs.apha.2020.05.002_bb0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","article-title":"Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression","volume":"155","author":"Shiroma","year":"2014","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: A systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/bs.apha.2020.05.002_bb0205","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"The American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/bs.apha.2020.05.002_bb0210","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2020.05.002_bb0215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1176\/appi.ajp.157.2.229","article-title":"Multiple recurrences of major depressive disorder","volume":"157","author":"Solomon","year":"2000","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/bs.apha.2020.05.002_bb0220","unstructured":"Spravato\u2122 (esketamine) nasal spray prescribing information (2019). Titusville, NJ: Janssen Pharmaceuticals Companies."},{"key":"10.1016\/bs.apha.2020.05.002_bb0225","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jad.2016.09.008","article-title":"Continuation phase intravenous ketamine in adults with treatment-resistant depression","volume":"206","author":"Vande Voort","year":"2016","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/bs.apha.2020.05.002_bb0230","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jad.2017.09.024","article-title":"Corrigendum to \u201ccontinuation phase intravenous ketamine in adults with treatment-resistant depression\u201d","volume":"236","author":"Vande Voort","year":"2018","journal-title":"Journal of Affective Disorders"},{"issue":"3","key":"10.1016\/bs.apha.2020.05.002_bb0235","doi-asserted-by":"crossref","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2020.05.002_bb0240","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2020.05.002_bb0245","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale psychiatric hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2020.05.002_bb0250","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA)","volume":"192","author":"Williams","year":"2008","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/bs.apha.2020.05.002_bb0255","author":"World Health Organization"},{"issue":"3","key":"10.1016\/bs.apha.2020.05.002_bb0260","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacological Reviews"},{"issue":"8","key":"10.1016\/bs.apha.2020.05.002_bb0265","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Archives of General Psychiatry"}],"container-title":["Advances in Pharmacology","Rapid Acting Antidepressants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358920300284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358920300284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:43:55Z","timestamp":1760960635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358920300284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128201893"],"references-count":52,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2020.05.002","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}